Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial.
Dana-Farber Cancer Institute has received a $50 million donation from Judith B. Hale, her son, Robert T. Hale, Jr., and his wife, Karen Hale, to support the Hale Family Center for Pancreatic Cancer Research.
Christopher Lathan was named chief clinical access and equity officer, a new institutional leadership position, at Dana-Farber Cancer Institute.
MD Anderson Cancer Center and the Broad Institute of MIT and Harvard have established a translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community.
Jordan Anaokar was named site director for radiology at Fox Chase Cancer Center. In her new role, Anaokar will coordinate with medical staff and the Department of Radiology in developing and implementing departmental programs in addition to her clinical care, research, and teaching.
Pawel Kalinski was named Jacobs Family Endowed Chair of Immunology, chief of the Division of Translational Immuno-Oncology, and senior vice president for team science at Roswell Park Comprehensive Cancer Center.
Jeffrey Miller, deputy director of the Masonic Cancer Center, and his research team have been awarded a $9 million NCI grant for his program titled “NK cells, their receptors, and cancer therapy.”
The Leukemia & Lymphoma Society has awarded three IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants worth a combined total of $3.6 million to Mayo Clinic, Vanderbilt University Medical Center, and Weill Cornell Medicine.
The Melanoma Research Foundation has issued Request for Proposals for the 2021 Career Development Awards.
The phase III KEYNOTE-522 trial investigating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as an adjuvant treatment after surgery met its dual primary endpoint of event-free survival for the treatment of patients with high-risk early-stage triple-negative breast cancer.
